National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost Effectiveness of Roflumilast (Daxas®) for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
11/06/2010 03/11/2010 Reimbursement not recommended.

We do not recommend reimbursement of Roflumilast (Daxas®) under the Community Drugs Schemes.

Roflumilast Evaluation Summary